Ian McCoy’s Post

AstraZeneca has become Britain’s first £200bn company following a 20pc rally in its share price since the start of the year. Shares in the pharmaceutical business rose 1.1pc yesterday to value the company at £200.3bn. AstraZeneca’s stock has surged so far this year amid strong sales of its roster of cancer and rare disease ­medicines. The drug company jumped ahead of Shell in April to become the most valuable business on the FTSE 100. AstraZeneca surpassed its long-term revenue targets last year, generating $45.8bn (£35.7bn) of sales compared with $25.7bn in 2014.  It said in May it was now targeting annual revenues of $80bn by 2030, claiming it was embarking on a “new era of growth”. Pascal Soriot, the AstraZeneca chief executive, said many of the treatments it was developing had the potential to generate more than $5bn of revenue in a year. It is aiming to launch a further 20 new medicines before the end of the decade. As part of this push, AstraZeneca struck a £1.6bn deal in November for an experimental weight loss pill being developed by Chinese biotech company Eccogene. Full article: https://lnkd.in/eD8S3WvK

🥐 De bonnes nouvelles pour la #France ce matin! 🥐 💊 Leading pharmaceutical companies like Sanofi, GSK, Pfizer, and AbbVie are making substantial investments in R&D, clinical research, and drug production in northern France. 🔬 These initiatives are expected to generate over 800 new #jobs between 2024 and 2026 and produce top-tier #pharmaceuticals. 💲 Sanofi's commitment alone, with over 1 billion euros earmarked for expanding manufacturing capacity and constructing a new facility in Vitry-sur-Seine, highlights the region's emergence as a hub for innovation in healthcare. 📈 The investments not only foster economic growth but also underscore the companies' dedication to advancing healthcare solutions and creating opportunities for skilled professionals. https://lnkd.in/d6SWTUwa

A move to Coventry opens up UK market for Pharma company 💊👀 A pharmaceutical company which helps patients with complex needs access vital treatments not widely available is set to relaunch itself into the UK market after a move to Coventry. Komtur Pharmaceuticals has opened a new office at the Business Innovation Centre in Binley, part of the University of Warwick Science Park, to help improve outcomes for patients with rare diseases or chronic conditions that need treatments that are not easily obtainable through organisations like the NHS. The firm works with healthcare professionals and drug companies around the world to provide these treatments, and also helps bring new medicines come to market by supplying similar drugs to manufacturers for comparisons in clinical trials. Continue reading... https://lnkd.in/e4weJabt #property #pharmaceuticals #science #realestate #commercialproperty #growth #coventrynews #coventryhour #businessnews #businessintelligence

# Only put off until tomorrow what you are willing to die having left undone ## Ivan H. Cheung Elected to Board of Directors of Lexicon Pharmaceuticals, Inc. Lexicon Pharmaceuticals, a leading biopharmaceutical company, has recently announced the election of Ivan H. Cheung to its esteemed Board of Directors. Ivan Cheung brings with him over 25 years of extensive experience in the biopharmaceutical sector, making him a highly valuable addition to the board. With his remarkable track record and current role as CEO in the industry, Cheung's appointment further strengthens Lexicon Pharmaceuticals' expertise in advancing innovative healthcare solutions. His vast knowledge and leadership abilities will significantly contribute to the company's strategic decision-making process. Investing in healthcare is a critical component of any well-diversified portfolio, and the inclusion of prominent professionals like Ivan H. Cheung in pharmaceutical companies emphasizes the industry's commitment to excellence. As an investor, it is essential to stay informed about such noteworthy developments to make informed decisions and capitalize on opportunities. Don't miss out on the latest advancements in healthcare and seize the opportunity to grow your Health Savings Account through investing. Act now to ensure you are part of this transformative journey towards improving global health and wellbeing. #hsa #investing #healthcare #health #family #wellness 💼💸🏥🌿👪💪

#AstraZeneca completed the acquisition of #AmolytPharma, a clinical-stage biotechnology company focused on developing novel treatments for rare #endocrine diseases. This acquisition bolsters AstraZeneca's #RareDisease late-stage pipeline and expands on its #bonemetabolism portfolio with the addition of #Eneboparatide (#AZP3601). Follow RAS LifeScience Solutions for more such industry updates. #raslss #raslssupdate #pharmanews #pharmaupdate #acquisition

The top 20 #biopharma companies reported a 2% growth in #marketcap in Q3 2024 amid a flurry of drug approvals such as Bristol Myers Squibb's #Cobenfy and Gilead Sciences' #Livdelzi, as well as interest rate cuts by the US Federal Reserve. Is the biopharmaceutical industry poised for a recovery? Check out more in my GlobalData Healthcare analyst briefing!

Looking at the 20 top pharma companies by market cap reveals some clear trends, yet others are more subtle: While Eli Lilly and Company and Novo Nordisk have long been in the top 20, only in the last ~2 years have they broken into the top tier, thanks to their GLP-1s. Lilly is now among the 10 most valuable companies in the world, across all industries. While weight loss drugs have gotten the headlines, others delivered impressive gains over the last 3 years as well: AstraZeneca increased its value by ~50%, largely thanks to its strong oncology portfolio, with blockbusters like Tagrisso that delivered ~$6B in sales in FY2023. Meanwhile, Regeneron and Vertex Pharmaceuticals almost doubled their value, driven by Dupixent/Eylea and Trikafta respectively. One of the most surprising results is from AbbVie, which increased its market cap from ~$200B to ~$300B in the last 3 years, despite the fact its best-seller Humira began to face competition during that time.

Alembic Pharma Posts 17 Pecent Increase In Q4 Profit Alembic Pharmaceuticals Limited, an Indian generic drug manufacturer, has announced a 17 percent rise in fourth-quarter profit, propelled by strong sales, especially in the crucial North American market. Consolidated profit rose to 1.78 billion rupees ($21.3 million) in the three months ended March 31, from 1.53 billion rupees a year earlier. As per Reuters Report, Indian generic drugmakers like Dr. Reddy's Laboratories, Cipla and SUN PHARMA have been benefitting from price recovery in the U.S. market as well as strong sales, especially of their copycat versions of Bristol Myers Squibb blockbuster cancer drug Revlimid. On Tuesday, Dr Reddy's beat fourth-quarter profit estimates, boosted by strong U.S. sales of its generic version of Revlimid. #alembicphama #alembicpharmanews #financialresults

AstraZeneca 𝐡𝐚𝐬 𝐚𝐧𝐧𝐨𝐮𝐧𝐜𝐞𝐝 𝐚𝐧 𝐚𝐦𝐛𝐢𝐭𝐢𝐨𝐮𝐬 𝐠𝐨𝐚𝐥 𝐭𝐨 𝐛𝐨𝐨𝐬𝐭 𝐢𝐭𝐬 𝐫𝐞𝐯𝐞𝐧𝐮𝐞 𝐛𝐲 𝟕𝟓% 𝐭𝐨 $𝟖𝟎 𝐛𝐢𝐥𝐥𝐢𝐨𝐧 𝐛𝐲 𝟐𝟎𝟑𝟎. This growth is expected to be driven by the launch of 20 new medicines and the expansion of its current oncology, biopharmaceuticals, and rare disease portfolios. 𝐂𝐄𝐎 𝐏𝐚𝐬𝐜𝐚𝐥 𝐒𝐨𝐫𝐢𝐨𝐭, who has significantly revitalized the company's drug pipeline over the past decade, highlighted that many of these new medicines could each generate over $5 billion in peak year revenues. Despite facing patent expirations on some key drugs, AstraZeneca plans to invest in new technologies and platforms to sustain its growth beyond 2030. Analysts are keenly watching the company's investor day event for detailed insights into its pipeline assets and their market potential. https://lnkd.in/dZxxjuvF #PharmaGrowth #AstraZeneca #BiotechInnovation #NewMedicines #HealthcareInvestment #pharma

Australia’s reputation for early phase clinical trials is making it the first choice for international pharmaceutical companies developing new drugs and therapies. #Australia #Clinicaltrials #Clinicaltrialsinaustralia